Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29183557 | 0.89 | KDM4E (0.63) | KDM4EPOLBGAARAB9AMAPT | |
| SCHEMBL19389669 | 0.86 | KDM4E (0.63) | KDM4EPOLBGAARAB9AMAPT | |
| SCHEMBL3770491 | 0.84 | KDM4E (0.60) | KDM4EPOLBGAARAB9AMAPT | |
| SCHEMBL871014 | 0.83 | KDM4E (0.69) | KDM4EPOLBGAARAB9AMAPT | |
| SCHEMBL21001637 | 0.83 | KDM4E (0.59) | KDM4EPOLBGAARAB9AMAPT | |
| SCHEMBL23534246 | 0.81 | KDM4E (0.56) | KDM4EPOLBGAARAB9AMAPT | |
| SCHEMBL21033285 | 0.81 | KDM4E (0.56) | KDM4EPOLBGAARAB9AMAPT | |
| SCHEMBL22531821 | 0.81 | KDM4E (0.56) | KDM4EPOLBGAARAB9AMAPT | |
| SCHEMBL22531299 | 0.81 | KDM4E (0.56) | KDM4EPOLBGAARAB9AMAPT | |
| SCHEMBL118658 | 0.80 | KDM4E (0.66) | KDM4EPOLBGAARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704120-B1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | JUBILANT EPISCRIBE LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| EP-3704120-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | Jubilant Episcribe LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | KDM4E 221/4885POLB 1269/4885GAA 3971/4885 |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | KDM4E 221/4885POLB 1269/4885GAA 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.